Testing of Afsanteen and Araq-e-Mako in the infection of upper genital tract in females.

Clinical efficacy of Afsanteen Artemisia absinthium Linn and Araq e Mako in uncomplicated Pelvic Inflammatory Disease An open randomized standard control trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/074855

Enrollment

Registered

2024-10-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere

Interventions

Intervention1: Afsanteen (Artemesia absinthium Linn.) powder and Araq-e-Mako: Afsanteen powder 3gm twice a day orally for 14 days and Araq-e-Mako 60ml twice a day orally for 14 days Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: Married women in the age group of 18 to 45 years Patient complaining of abnormal vaginal discharge mucopurulent yellow or green pelvic or lower abdominal pain low backache pelvic discomfort dysuria dyspareunia and the presence of leucorrhea defined as WBC greater than 10 in the saline microscopy of vaginal fluid Patient with presence of one of the minimum criteria cervical motion tenderness lower abdominal pain uterine tenderness Bilateral adnexal tenderness as per CDC guideline

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Acute cases and PID with surgical emergencies Patient with severe PID tubo ovarian abscess haemorrhagic ovarian cyst appendicitis and pelvic pain more than 30 days history of abortion any pelvic abdominal or gynaecological surgery less than 30 days Use of systemic antibacterial therapy less than 7 days before enrolment Women with history of UTI HIV or syphilis or malignancy Patients suffering from Diabetes genital Tuberculosis cardiovascular An inability or intolerance to an oral antibiotic regimen

Design outcomes

Primary

Measure	Time frame
VASscore for lower abdominal pain, lower backache Modified McCormack Pain Scale for pelvic tendernessTimepoint: assessment of patient will be done at initial day, day 3, day 7. and day 14	—

Secondary

Measure	Time frame
EQ-5D-5L questionnaireTimepoint: assessment of patient will be done on initial day, day 3, day 7, and day 14	—

Countries

India

Contacts

Public ContactProf Suboohi Mustafa

Ajmal Khan Tibbiya College and Hospital Aligarh Muslim University

drsuboohi_m@yahoo.com9411413788

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026